Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock

Tariq A. Aziz, Gurpal Singh, Eric Popjes, Edward Stephenson, Suzanne Mulvey, Walter Pae, Aly El-Banayosy

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background: Cardiogenic shock refractory to conventional therapy has very high mortality and limited support options. New technology with peripherally inserted CentriMag (Levitronix LLC, Waltham, MA) extracorporal membrane oxygenation (ECMO) may have the potential to significantly improve survival in these critically ill patients. Outcomes of the first 10 patients to receive this device at our institutions are presented. Methods: Patients were identified by their primary physicians and evaluated by our Mechanical Circulatory Support Team. CentriMag ECMO was initiated at the bedside using sterile percutaneous cannulation of femoral vessels. Patients were admitted to the Heart and Vascular Intensive Care Unit, with care managed by regular nursing staff with special training. Results: The patients (5 men, 5 women) were a mean age of 45 ± 18 years, had a mean left ventricular ejection fraction of 30%, and a mean lactate level of 9 mmol/liter. All patients met criteria for shock refractory to medical therapy, but the etiology varied. Average duration of ECMO support was 5.8 ± 4 days. Survival was 60%. There were no major complications directly related to the device and no equipment malfunctions. Conclusions: The peripherally inserted CentriMag ECMO was easy to insert, functioned without mechanical error, and significantly reduced expected mortality in critically ill patients. Further research will be necessary to develop standardized algorithms and gain more experience, but this new technology has promising potential.

Original languageEnglish (US)
Pages (from-to)66-71
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Cardiogenic Shock
Critical Illness
Membranes
Equipment Failure
Technology
Equipment and Supplies
Survival
Mortality
Nursing Staff
Managed Care Programs
Thigh
Catheterization
Stroke Volume
Blood Vessels
Intensive Care Units
Shock
Lactic Acid
Physicians
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

@article{0578377735be49669c828806669e44f1,
title = "Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock",
abstract = "Background: Cardiogenic shock refractory to conventional therapy has very high mortality and limited support options. New technology with peripherally inserted CentriMag (Levitronix LLC, Waltham, MA) extracorporal membrane oxygenation (ECMO) may have the potential to significantly improve survival in these critically ill patients. Outcomes of the first 10 patients to receive this device at our institutions are presented. Methods: Patients were identified by their primary physicians and evaluated by our Mechanical Circulatory Support Team. CentriMag ECMO was initiated at the bedside using sterile percutaneous cannulation of femoral vessels. Patients were admitted to the Heart and Vascular Intensive Care Unit, with care managed by regular nursing staff with special training. Results: The patients (5 men, 5 women) were a mean age of 45 ± 18 years, had a mean left ventricular ejection fraction of 30{\%}, and a mean lactate level of 9 mmol/liter. All patients met criteria for shock refractory to medical therapy, but the etiology varied. Average duration of ECMO support was 5.8 ± 4 days. Survival was 60{\%}. There were no major complications directly related to the device and no equipment malfunctions. Conclusions: The peripherally inserted CentriMag ECMO was easy to insert, functioned without mechanical error, and significantly reduced expected mortality in critically ill patients. Further research will be necessary to develop standardized algorithms and gain more experience, but this new technology has promising potential.",
author = "Aziz, {Tariq A.} and Gurpal Singh and Eric Popjes and Edward Stephenson and Suzanne Mulvey and Walter Pae and Aly El-Banayosy",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.healun.2009.08.025",
language = "English (US)",
volume = "29",
pages = "66--71",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "1",

}

Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock. / Aziz, Tariq A.; Singh, Gurpal; Popjes, Eric; Stephenson, Edward; Mulvey, Suzanne; Pae, Walter; El-Banayosy, Aly.

In: Journal of Heart and Lung Transplantation, Vol. 29, No. 1, 01.01.2010, p. 66-71.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Initial experience with CentriMag extracorporal membrane oxygenation for support of critically ill patients with refractory cardiogenic shock

AU - Aziz, Tariq A.

AU - Singh, Gurpal

AU - Popjes, Eric

AU - Stephenson, Edward

AU - Mulvey, Suzanne

AU - Pae, Walter

AU - El-Banayosy, Aly

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Cardiogenic shock refractory to conventional therapy has very high mortality and limited support options. New technology with peripherally inserted CentriMag (Levitronix LLC, Waltham, MA) extracorporal membrane oxygenation (ECMO) may have the potential to significantly improve survival in these critically ill patients. Outcomes of the first 10 patients to receive this device at our institutions are presented. Methods: Patients were identified by their primary physicians and evaluated by our Mechanical Circulatory Support Team. CentriMag ECMO was initiated at the bedside using sterile percutaneous cannulation of femoral vessels. Patients were admitted to the Heart and Vascular Intensive Care Unit, with care managed by regular nursing staff with special training. Results: The patients (5 men, 5 women) were a mean age of 45 ± 18 years, had a mean left ventricular ejection fraction of 30%, and a mean lactate level of 9 mmol/liter. All patients met criteria for shock refractory to medical therapy, but the etiology varied. Average duration of ECMO support was 5.8 ± 4 days. Survival was 60%. There were no major complications directly related to the device and no equipment malfunctions. Conclusions: The peripherally inserted CentriMag ECMO was easy to insert, functioned without mechanical error, and significantly reduced expected mortality in critically ill patients. Further research will be necessary to develop standardized algorithms and gain more experience, but this new technology has promising potential.

AB - Background: Cardiogenic shock refractory to conventional therapy has very high mortality and limited support options. New technology with peripherally inserted CentriMag (Levitronix LLC, Waltham, MA) extracorporal membrane oxygenation (ECMO) may have the potential to significantly improve survival in these critically ill patients. Outcomes of the first 10 patients to receive this device at our institutions are presented. Methods: Patients were identified by their primary physicians and evaluated by our Mechanical Circulatory Support Team. CentriMag ECMO was initiated at the bedside using sterile percutaneous cannulation of femoral vessels. Patients were admitted to the Heart and Vascular Intensive Care Unit, with care managed by regular nursing staff with special training. Results: The patients (5 men, 5 women) were a mean age of 45 ± 18 years, had a mean left ventricular ejection fraction of 30%, and a mean lactate level of 9 mmol/liter. All patients met criteria for shock refractory to medical therapy, but the etiology varied. Average duration of ECMO support was 5.8 ± 4 days. Survival was 60%. There were no major complications directly related to the device and no equipment malfunctions. Conclusions: The peripherally inserted CentriMag ECMO was easy to insert, functioned without mechanical error, and significantly reduced expected mortality in critically ill patients. Further research will be necessary to develop standardized algorithms and gain more experience, but this new technology has promising potential.

UR - http://www.scopus.com/inward/record.url?scp=72249098773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249098773&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2009.08.025

DO - 10.1016/j.healun.2009.08.025

M3 - Article

C2 - 19837609

AN - SCOPUS:72249098773

VL - 29

SP - 66

EP - 71

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 1

ER -